




**Figure S1. Immunohistochemistry staining negative control.** Immunohistochemistry analysis of a TNBC sample incubated with all reagents but no primary antibody.



**Figure S2. Whole western blotting image staining.** AnxA1 and Lamin B2 staining in nuclear extracts of normal breast and BC cell lines. Membrane has been cut to incubate with anti-Lamin B2 or anti-AnxA1 antibody separately.



**Figure S3.** (A) Western blotting cropped images of AnxA1 expression in MDA-MB-231 expressing a shRNA control (shCRT) or a shRNA specific for AnxA1 (shAnxA1). (B) IL-6 expression levels in supernatants of MDA-MB-231 cells expressing shCRT or shAnxA1.



**Figure S4.** (A) Quantification of gap closure of wound healing assay of HFF cells upon stimulation with supernatants of MDA-MB-231 cells treated as stated in the graph. (B)

Quantification of gap closure of wound-healing assay of HFF cells upon stimulation with supernatants of MDA-MB-157 cells treated as stated in the graph. (C) Quantification of gap closure of wound-healing assay in MDA-MB-231 cells expressing a shRNA control (shCRT) or a shRNA specific for AnxA1 (shAnxA1). \*  $p < 0.05$ ; \*\*  $p < 0.001$ .